Swiss -based company Roche was the global leader based on oncology market share in 2017 and is forecasted to maintain this position until 2024. However, it is expected that the market share will decrease dramatically from the current 26 percent to under 12 percent by 2024. The main reason for this development is that competitors like Celgene, Bristol Myers-Squibb, and Johnson and Johnson will dominate with their key oncology products by that year. Additionally, several of Roche’s blockbuster oncologic drugs will face sales erosion due to biosimilar competition.

Oncology market overview

The oncology market is expected to increase with a compound annual growth rate of twelve percent worldwide between 2017 and 2024. Traditionally, oncology is one of the three leading therapy classes worldwide by spending, accompanied by pain medication and antidiabetics. Around 45 percent of the global market is generated in the United States alone, making it the world’s top national oncology market. Another 20 percent of the market remains in the leading five EU- countries. At this moment, the three best-selling cancer drugs worldwide are Celgene’s Revlimid and Roche’s Rituxan and Herceptin.

The rise of immune-oncology

The aim in immunotherapy is the same as with immunizations (vaccinations) – to use the human body’s inherent defenses to fight the disease. Immune-oncology is a type of immunotherapy that specifically targets cancer cells. The great advantage of immune-oncology is the targeted approach, which leaves the rest of the body unharmed compared to traditional treatments. The fight against the many types of cancer is still one of the great challenges in modern medicine and personalized treatments already show huge potential. The global cancer immunotherapy market is projected to reach 117 billion U.S. dollars by 2022.

The global AI in oncology market size was valued at USD 1.1 billion in 2023 to USD 9.1 billion by 2035, with a noteworthy CAGR of 21.4%.

The Report Covers Global Interventional Oncology Companies and the Market is Segmented by Product Type (Ablation Devices (Microwave Ablation, Radiofrequency Ablation, Cryoablation, and Other Product Types) and Embolization Devices (Microcatheters, Guidewires, and Others), Cancer Type (Lung Cancer, Breast Cancer, Liver Cancer, Kidney Cancer, Prostate Cancer, and Other Cancer Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Value (in USD) for the Above Segments.

Global Precision Oncology Market size is expected to be worth around USD 202.5 Billion by 2032 from USD 89.3 Billion in 2023

The size and share of the market is categorized based on Type (Software Solutions, Hardware, Services) and Application (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

This statistic shows a projection of the global spending and growth in the oncology market between 2023 and 2027. In 2023, oncology spending is expected to be around 218 billion U.S. dollars worldwide. Spending in this market is expected to increase to over 370 billion dollars by 2027. The maximum projection for the 2023-2027 CAGR is 16 percent.

According to Future Market Insights research, during the projected period, the global orthopedic oncology market is expected to grow at a CAGR of 6.5%. The market value is projected to increase from US$ 1.2 Billion in 2023 to US$ 2.3 Billion by 2033. The orthopedic oncology market was valued at US$ 1.1 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 7.2% in 2023.

Data Points	Market Insights
Market Value 2022	US$ 1.1 Billion
Market Value 2023	US$ 1.2 Billion
Market Value 2033	US$ 2.3 Billion
CAGR 2023 to 2033	6.5%
Market Share of Top 5 Countries	54.1%
Key Market Players	General Electric (GE) Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Hitachi Medical Systems, Hologic, Shimadzu Medical Systems, Carestream Health, Canon Medical Systems, FUJIFILM Medical Systems, Ziehm Imaging, Planmed Oy, EOS imaging, Medtronic plc, Stryker Corporation, Cook Medical, Zimmer Biomet, Biopsybell, Becton Dickenson & Company, and Teleflex Inc.

Report Scope as Per Orthopedic Oncology Industry Analysis

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2017 to 2022
Market Analysis	US$ Million for Value
Key Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Middle East and Africa (MEA)
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye Northern Africa and South Africa.
Key Market Segments Covered	Diagnostic Techniques, Cancer Stage, Indications, End User, and Region
Key Companies Profiled	General Electric (GE) Healthcare Siemens Healthineers Koninklijke Philips N.V. Hitachi Medical Systems Hologic Shimadzu Medical Systems Carestream Health Canon Medical Systems FUJIFILM Medical Systems Ziehm Imaging Planmed Oy EOS imaging Medtronic plc Stryker Corporation Cook Medical Zimmer Biomet Biopsybell Becton Dickenson & Company Teleflex Inc.
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

The global oncology market is anticipated to reach a value of USD XX million by 2033, expanding at a CAGR of 5.40% during the forecast period (2025-2033). The market growth is attributed to the increasing prevalence of cancer, advancements in cancer treatments, and government initiatives to support cancer research and treatment. Moreover, the growing geriatric population, unhealthy lifestyles, and environmental factors are also contributing to the market's growth. Key market trends include the increasing adoption of personalized and targeted therapies, the rise of immuno-oncology drugs, and the growing focus on early diagnosis and screening. However, factors such as the high cost of cancer treatments and the limited accessibility to healthcare in developing countries are expected to restrain the market growth to some extent. The major market players include Bristol Myers Squibb company, Boehringer Ingelheim GmbH, Sanofi, Astellas Pharma Inc, Novartis AG, Merck & Co Inc, AstraZeneca PLC, Eli Lilly and Company, F Hoffmann-La Roche Ltd, AbbVie Inc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, GlaxoSmithKline PLC, and Pfizer Inc. Recent developments include: In June 2022, Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status., In March 2021, Merck Sharp & Dohme Corp. started a phase II clinical trial to evaluate the safety and efficacy of fixed-dose co-formulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in patients with hepatocellular carcinoma (HCC).. Key drivers for this market are: Growing Burden of Cancer Worldwide, Increasing Role of Precision and Personalized Medicine for Cancer Treatment. Potential restraints include: Stringent Regulations for Patient Enrollment. Notable trends are: Lung Cancer Segment is Expected to Hold Significant Market Growth Over the Forecast Period.

This statistic displays the top oncology products worldwide by projected market share for 2024, and their market shares in 2017. Cancer drug Opdivo from Bristol-Myers Squibb and Ono Pharmaceutical is expected to keep its position with a market share of five percent.

Top oncology products

Oncological products generate a significant proportion of their revenue in the United States and in Europe. In 2012, oncology spending totaled nearly 50 billion U.S. dollars in the United States and 22 billion U.S. dollars in the leading five EU-countries. Oncology is among the top therapy classes in the pharmaceutical market.

Among the top oncology products in 2017 were Keytruda and Opdivo, generating 3.8 and 5.7 billion U.S. dollars on the worldwide market. Top cancer drug Rituxan is marketed by Roche and is used to treat diseases such as lymphomas, leukemias, transplant rejections, and autoimmune disorders. Bevacizumab, marketed as Avastin also under Roche, is used to slow down the growth rate of new blood vessels. It can be used to treat cancers such as those originating in the colorectum, lung, breast, or kidney. Roche has a stronghold on the global oncology market. In 2017, Roche maintained a share of over 26 percent of the market but is expected to drop to some 12 percent of the market in 2024. Roche or Hoffman-La Roche is a Swiss company that was founded in 1896. The company focuses primarily on pharmaceutical products and diagnostics. Roche generated more than 53 billion Swiss francs in revenue in 2017, making it one of the most successful biotech and pharmaceutical companies in the world.

Global Precision Immuno-Oncology Market was valued at USD 62.24 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.85% through 2030.

Pages	180
Market Size	2024: USD 62.24 Billion
Forecast Market Size	2030: USD 109.61 Billion
CAGR	2025-2030: 9.85%
Fastest Growing Segment	Checkpoint Inhibitors
Largest Market	North America
Key Players	1. Adaptimmune Therapeutics Plc 2. Agenus Inc. 3. Amgen Inc 4. AstraZeneca plc 5. Bristol Myers Squibb Company 6. Celgene Corporation 7. Eli Lilly and Company 8. F. Hoffmann-La Roche Ltd. 9. Gilead Sciences, Inc 10. GlaxoSmithKline Plc

In 2019, around 71 percent of the total oncology drug market in the United States were generated by the 20 top-selling cancer medicines. The share of 20 top-selling medicines in the United Kingdom was around 58 percent of the total oncology market.

Snapshot img

Radiation Oncology Market Size 2024-2028

The radiation oncology market size is forecast to increase by USD 1.94 billion at a CAGR of4.34% between 2023 and 2028.

In the market, the primary drivers include the increasing incidence of cancer and the rise in healthcare expenditure. As cancer continues to be a significant health concern, the demand for advanced radiation therapy techniques, such as seeds and stereotactic therapy, is increasing. These treatments offer therapeutic benefits by targeting abnormal cells with precision, reducing the impact on healthy cells. Technological developments, including advanced treatment planning software, tumor tracking systems, artificial intelligence, and machine learning, enable more effective and personalized treatment plans. However, challenges persist, including the lack of access to radiotherapy in certain regions and the high cost of these advanced treatments. Despite these challenges, the market is expected to grow, driven by the potential for improved patient outcomes and the ongoing technological advancements In the field.

What will be the Size of the Radiation Oncology Market During the Forecast Period?

Request Free Sample

The market is a significant segment of the healthcare industry, focusing on the delivery of radiation therapy to treat various types of cancer. This form of oncology treatment, also known as radiotherapy, utilizes high-energy radiation to destroy tumor cells. Radiation oncology plays a crucial role in cancer treatment, with breast cancer, metastatic melanoma, and neuroendocrine cancers being some of the common indications. The increasing prevalence of cancer and the growing demand for advanced therapeutic benefits have driven the market's growth. Regulatory scrutiny remains a critical factor In the market.



Stringent regulations ensure the safety and efficacy of radiotherapy devices and treatment planning software. These regulations also apply to advanced technologies like proton therapy, which offers improved therapeutic benefits for certain types of cancer. Imaging data plays a pivotal role in radiation oncology. Accurate and timely access to imaging data is essential for effective treatment planning and delivery. Cancer treatment centers and oncology research institutes are investing in advanced imaging technologies to enhance their capabilities. Technological developments in radiation oncology are continually evolving. Companies are focusing on improving the precision, efficiency, and patient experience of radiotherapy. Radiotherapy devices, such as those manufactured by Elekta and Gamma Knife, are being enhanced with innovative features.

How is this Radiation Oncology Industry segmented and which is the largest segment?

The radiation oncology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  EBRT
  Brachytherapy


Application

  Breast cancer
  Lung cancer
  Penile cancer
  Prostate cancer
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Type Insights

The EBRT segment is estimated to witness significant growth during the forecast period.

Radiation oncology, a specialized medical field focusing on the use of radiation to treat various types of cancer, encompasses external beam radiation therapy (EBRT). EBRT utilizes high-energy beams, typically generated by a Linear Accelerator (LINAC, the most common technology), to target and destroy cancer cells. These beams can be delivered as X-rays, electrons, or other particles, such as protons. EBRT plays a crucial role in treating numerous cancer types, including breast cancer, colorectal cancer (CRC), cervical cancer, esophageal cancer, head and neck cancer, lung cancer, prostate cancer, and brain tumors. Advanced radiotherapy systems, such as CyberKnife, Gamma Knife, and TomoTherapy, are also part of the EBRT market.

Furthermore, proton therapy, which uses cyclotrons and synchrotrons, is another subset of EBRT. Among these technologies, LINAC holds the largest market share In the market. By providing precise and effective cancer treatment, these advanced technologies contribute significantly to cancer treatment centers across the US and North America, ensuring improved patient outcomes and quality of life.

Get a glance at the Radiation Oncology Industry report of share of various segments Request Free Sample

The EBRT segment was valued at USD 6.22 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

Europe is estimated to contribute 39% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends

The GCC Oncology/Cancer Drugs Market is predicted to grow at a considerable CAGR during 2023-28, says MarkNtel Advisors.

Precision Oncology Market Report is Segmented by Type (Therapeutics, Diagnostics), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Cancer Types), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies Research & Academic Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

The global radiation oncology market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.3% during 2025-2033. Technological advancements, rising cancer incidence, increasing awareness regarding oncology radiation, government initiatives, and collaborations, regulatory approvals for new therapies, and the trend towards personalized medicine are some of the factors fostering the market growth.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 8.6 Billion
Market Forecast in 2033	USD 14.9 Billion
Market Growth Rate 2025-2033	6.3%

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on the type, technology, application, and end user.

Introduction

Global Oncology Market size is expected to be worth around US$ 628 Billion by 2032 from US$ 233 Billion in 2023, growing at a CAGR of 12% during the forecast period from 2023 to 2032. North America held a strong lead in 2022, reaching US$ 84.2 Billion in revenue.

Cancer ranks as the world's third deadliest disease, following cardiovascular and infectious diseases. Chemoprevention involves using synthetic or natural agents to prevent cancer development. Primary cancer treatments include surgery, often the first-line treatment in early stages, radiotherapy, typically used alongside surgery, and pharmacotherapy, including chemotherapy and targeted therapy that focuses on genetic alterations in cancer cells.

Increased consumption of alcohol and tobacco has led to a rise in the global oncology burden. This, combined with intensive industry efforts to develop new cancer treatments, underpins steady market growth. The field leverages diverse educational tools and online resources, expanding patient access to information and boosting demand for oncology services.

Despite high treatment costs posing barriers, the cancer treatment market is poised for growth due to rising cancer prevalence, aging populations, and ongoing research and development. This growth is further supported by government initiatives and private investments, offering substantial opportunities for firms to deliver innovative and cost-effective cancer care solutions.

https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1216,h_710/https://market.us/wp-content/uploads/2023/02/Oncology-Market-1.jpg" alt="Oncology-Market-1" class="wp-image-97127">

The U.S. ai In oncology market is expected to rise USD 7710.88 million by 2032 and anticipated to grow at a CAGR of 27.1%.

Global AI in oncology Market size will exceed a valuation of USD 16.72 billion by 2032, to grow at a CAGR of 33.6% during the forecast period.

In 2022, the global market for cancer drugs was estimated at 147 billion U.S. dollars. By 2032, this market is forecasted to reach over 300 billion U.S. dollars. This statistic illustrates the size of the cancer drug market worldwide in 2022 and 2032.

The global oncology precision medicine market size is estimated to grow from USD 147.9 billion in 2024 to USD 364 billion by 2035, representing a CAGR of 8.5%